The global Flutoprazepam market is anticipated to expand at substantial CAGR during the forecast period, between 2021 and 2028.
Flutoprazepam is a benzodiazepine which is available in Japan. It shows hypnotic, anxiolytic, anticonvulsant and sedative effects. It is used for the treatment for stomach ulcers and severe insomnia. Flutoprazepam does not fall under the international Convention on Psychotropic Substances of 1971 and is currently unscheduled in the United States. Benzodiazepines act as central nervous system depressants by boosting the activities of the neurotransmitter gamma-aminobutyric acid (GABA) on the benzodiazepine site of the GABA type A (GABAA) receptor. Anxiolytic and sedative effects, muscular relaxation, and anticonvulsive activity are among their effects.
Flutoprazepam is currently unregulated in the United States because it does not fall under the 1971 International Convention on Psychotropic Substances. Flutoprazepam is classified as a Class C-Schedule II drug, according to the Misuse of Drugs Act, in Singapore and a Schedule III psychotic substance in Thailand. Flutoprazepam is regulated in Hong Kong under Schedule 1 of the Chapter 134 Dangerous Drugs Ordinance. Only health professionals and university researchers are allowed to use flutoprazepam legally. Pharmacists can dispense the drug with a prescription. A punishment of $10000 (HKD) might be imposed on anyone who supplies the substance without a prescription. A fine of $5,000,000 (HKD) and life imprisonment are the penalties for trafficking or manufacturing the chemical. Possession of the substance for human consumption without a Department of Health licence is prohibited by a penalty of $1,000,000 (HKD) and/or seven years in prison.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing demand for Flutoprazepam from the pharmaceutical industry increase in prevalence of anxiety, seizures, insomnia is fueling the market growth.
- Rise in concern for prevention of stress and related conditions is also driving the market.
- This drug is not regulated in many regions, which in turn, is expected to hamper the market growth.
Scope of the report:
The report on Flutoprazepam market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes | Details |
Report Title | Flutoprazepam Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | By Diseases (Anxiety, insomnia, stomach ulcers, and others), End-users (Adult and Children) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Cayman Chemical and DC Chemicals Ltd |
Flutoprazepam Market Segment Insights:
The Anxiety segment is projected to hold significant market share
In the terms of diseases, the Flutoprazepam market can be segmented into anxiety, insomnia, stomach ulcers, and others. Anxiety disorders segment is expected to hold a significant market share in the benzodiazepine drugs. According to the World Health Organization (WHO), the projected number of persons living with anxiety disorders worldwide is 264 million in 2015. This is a 14.9 percent increase since 2005, owing to population growth and ageing. Females are more likely than males to suffer from anxiety disorders (4.6 percent in females compared to 2.6 percent in males at the global level). In 2017, anxiety was a major section of the worldwide benzodiazepine medication market, and this trend is projected to continue during the forecast period.
Adults segment to grow during the forecast period
On the basis of end-users, the market can be bifurcated into adults and children. The adult segment is expected to hold a significant share of the market during the forecast period due to increase in geriatric population and rise of population suffering from stress.
Asia Pacific dominates the global market
In terms of regions, the global Flutoprazepam market can be split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific constituted a significant share of the market in 2020 due to mergers and acquisitions conducted by key market players. The market in Asia Pacific is projected to expand at a significant CAGR during the forecast period due to growing prevalence of anxiety among population.
Segments
Diseases
- Anxiety
- Insomnia
- Stomach ulcers
- Others
End-users
Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Key Players
- Cayman Chemical
- DC Chemicals Ltd
Competitive Landscape
Key players in the Flutoprazepam market include Cayman Chemical and DC Chemicals Ltd. These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.